谷氨基CoA脱酶 (GCDH) 通过调节谷氨基卡尼丁水平,增加脏恶性瘤的风险
Xuanshuo Liu1, Bohua Chen2, Jianghao Yuan3
1Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, 300000, China. xuan19881114@163.com.
Discover oncology
|October 10, 2025
概括
这项研究表明,增加谷氨基CoA脱酶 (GCDH) 表达增加了脏恶性瘤 (RM) 风险,通过降低谷氨基卡尼水平. 这一发现凸显了谷氨基甲尼丁作为潜在的生物标志物和RM的治疗标.
科学领域:
- 生物化学 生物化学
- 遗传学 遗传学 是一个
- 在瘤学瘤学.
背景情况:
- 巨化是一种关键的翻译后修饰,涉及到各种癌症.
- 它在脏恶性瘤 (RM) 中的特定作用及其与基因表达和新陈代谢的相互作用尚未得到充分理解.
研究的目的:
- 调查谷氨酸-CoA脱酶 (GCDH) 和脏恶性瘤 (RM) 之间的因果关系.
- 探索谷氨酸甲酸代谢在这种协会中的作用.
主要方法:
- 整合全基因组关联研究 (GWAS) 的数据为RM,化相关基因表达 (eQTLGen) 和代谢物GWAS.
- 采用两个样本的门德尔随机化 (MR),基于总结数据的门德尔随机化 (SMR) 和调解分析.
主要成果:
- 增加GCDH表达与较高的RM风险显著相关 (OR=1.25,P=0.0045).
- 升高的GCDH表达降低了谷氨基甲尼丁水平,与RM风险相反相关.
- 谷氨基卡尼丁介于GCDH和RM之间的总效果的30.25%.
结论:
- GCDH可能通过降低谷氨基甲尼丁的调节来间接促进RM.
- 这项研究为脏恶性瘤的代谢途径提供了新的见解.
- 谷氨基尼丁 (Glutarylcarnitine) 成为潜在的诊断生物标志物和RM的治疗标.
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Mutagenicity and Carcinogenicity
1.9K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.9K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
Induced Pluripotent Stem Cells
5.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
5.4K


